Vol. 69 No. 3 (2023), CLINICAL CASES

Vol. 69 No. 3 (2023)

Lymphomatoid papulosis in a patient with recurrent Hodgkin's lymphoma: a clinical case

CLINICAL CASES

https://doi.org/10.37469/0507-3758-2023-69-3-549-554

Published 30.06.2023

Leonid Kramynin⁺⁻
Margarita Motalkina ⁺⁻
Larisa Filatova⁺⁻
Ilya Zyuzgin⁺⁻
Anna Artemyeva⁺⁻

Leonid Kramynin

НМИЦ онкологии им. Н. Н. Петрова

https://orcid.org/0000-0003-4542-8353

Margarita Motalkina

НМИЦ онкологии имени Н.Н.Петрова

Larisa Filatova

НМИЦ онкологии имени Н.Н.Петрова

https://orcid.org/0000-0002-0728-4582

Ilya Zyuzgin

НМИЦ онкологии имени Н.Н.Петрова

Anna Artemyeva

НМИЦ онкологии имени Н.Н.Петрова

https://orcid.org/0000-0002-2948-397X

##article.numberofdownloads## 128

##article.numberofviews## 224

pdf (Русский)

Keywords

lymphomatoid papulosis
Hodgkin's lymphoma
relapse of lymphoma
recurrent lymphoma

How to Cite

Kramynin, L., Motalkina , M., Filatova, L., Zyuzgin, I., & Artemyeva, A. (2023). Lymphomatoid papulosis in a patient with recurrent Hodgkin’s lymphoma: a clinical case. Voprosy Onkologii, 69(3), 549–554. https://doi.org/10.37469/0507-3758-2023-69-3-549-554

Abstract

Lymphomatoid papulosis is an extremely rare skin disease occurring with a frequency of 1.2 – 1.9 cases per 1 million people per year. It has a very favorable prognosis: the 5-year survival rate is about 100%. However, such patients have an increased risk of developing secondary tumors compared to the general population. Mycosis Fungoides and cutaneous or systemic anaplastic large cell lymphoma are most often associated with lymphomatoid papulosis. Cases of lymphomatoid papulosis and Hodgkin's lymphoma in one patient are isolated, which makes them unique and requires a multidisciplinary and individualized approach to treatment and monitoring. This article presents a clinical case of a patient with lymphomatoid papulosis, against the background of which classical Hodgkin's lymphoma recurred twice.

https://doi.org/10.37469/0507-3758-2023-69-3-549-554

##article.numberofdownloads## 128

##article.numberofviews## 224

pdf (Русский)

References

Assaf C, Gellrich S, Steinhoff M, et al. Cutaneous lymphomas in Germany: an analysis of the Central Cutaneous Lymphoma Registry of the German Society of Dermatology (DDG). J Dtsch Dermatol Ges. 2007;5(8):6628. doi:10.1111/j.1610-0387.2007.06337.x.

Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. 2022;36(7):17201748. doi:10.1038/s41375-022-01620-2.

Willemze R. Cutaneous T-cell lymphoma: epidemiology, etiology, and classification. Leuk Lymphoma. 2003;44 Suppl 3:S4954. doi:10.1080/10428190310001623766.

Namba H, Hamada T, Iwatsuki K. Human T-cell leukemia virus type 1-positive lymphomatoid papulosis. Eur J Dermatol. 2016;26(2):1945. doi:10.1684/ejd.2015.2707.

Kadin ME, Levi E, Kempf W. Progression of lymphomatoid papulosis to systemic lymphoma is associated with escape from growth inhibition by transforming growth factor-beta and CD30 ligand. Ann N Y Acad Sci. 2001;941:5968. doi:10.1111/j.1749-6632.2001.tb03711.x.

Wagner G, Rose C, Klapper Wet al. Lymphomatoid papulosis. J Dtsch Dermatol Ges. 2020;18(3):199205. doi:10.1111/ddg.14041.

Kempf W, Pfaltz K, Vermeer MH, et al. EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma. Blood. 2011;118(15):402435. doi:10.1182/blood-2011-05-351346.

Bekkenk MW, Geelen FA, van Voorst Vader PC, et al. Primary and secondary cutaneous CD30(+) lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment. Blood. 2000;95(12):365361.

Beljaards RC, Willemze R. The prognosis of patients with lymphomatoid papulosis associated with malignant lymphomas. Br J Dermatol. 1992;126(6):596602. doi:10.1111/j.1365-2133.1992.tb00106.x.

Olsen EA, Delzell E, Jegasothy BV. Second malignancies in cutaneous T cell lymphoma. J Am Acad Dermatol. 1984;10(2Pt1):197204. doi:10.1016/s0190-9622(84)70023-5.

Melchers RC, Willemze R, Bekkenk MW, et al. Frequency and prognosis of associated malignancies in 504 patients with lymphomatoid papulosis. J Eur Acad Dermatol Venereol. 2020;34(2):260266. doi:10.1111/jdv.16065.

Nowicka D, Mertowska P, Mertowski S, et al. Etiopathogenesis, diagnosis, and treatment strategies for lymphomatoid papulosis with particular emphasis on the role of the immune system. Cells. 2022;11(22):3697. doi:10.3390/cells11223697.

Wang HH, Myers T, Lach LJ, et al. Increased risk of lymphoid and nonlymphoid malignancies in patients with lymphomatoid papulosis. Cancer. 1999;86(7):12405.

Gan EY, Tang MB, Tan SH. Lymphomatoid papulosis: is a second lymphoma commoner among East Asians? Clin Exp Dermatol. 2012;37(2):11821. doi:10.1111/j.1365-2230.2011.04124.x.

Kunishige JH, McDonald H, Alvarez G, et al. Lymphomatoid papulosis and associated lymphomas: a retrospective case series of 84 patients. Clin Exp Dermatol. 2009;34(5):57681. doi:10.1111/j.1365-2230.2008.03024.x.

De Souza A, el-Azhary RA, Camilleri MJ, et al. In search of prognostic indicators for lymphomatoid papulosis: a retrospective study of 123 patients. J Am Acad Dermatol. 2012;66(6):92837. doi:10.1016/j.jaad.2011.07.012.

Wieser I, Oh CW, Talpur R, et al. Lymphomatoid papulosis: Treatment response and associated lymphomas in a study of 180 patients. J Am Acad Dermatol. 2016;74(1):5967. doi:10.1016/j.jaad.2015.09.013.

Cordel N, Tressières B, D'Incan M, et al. French study group on cutaneous lymphoma. frequency and risk factors for associated lymphomas in patients with lymphomatoid papulosis. Oncologist. 2016;21(1):7683. doi:10.1634/theoncologist.2015-0242.

AbuHilal M, Walsh S, Shear N. Associated hematolymphoid malignancies in patients with lymphomatoid papulosis: a canadian retrospective study. J Cutan Med Surg. 2017;21(6):507512. doi:10.1177/1203475417716366.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Most read articles by the same author(s)

Svetlana Kulyova , Ksenia Borokshinova , Irina Baldueva , Tatiana Nekhaeva , Anna Artemyeva , Natalia Efremova , Natalya Emelyanova , Alexei Novik , Sergey Novikov, Mikhail Girshovich , Evgeny Senchurov , Elvira Gumbatova , Rina Khabarova , Elena Mikhailova , Yulia Semenova , Gaziz Sakhautdinov , Experience with multitargeted antitumor vaccine in a child with diffuse midline glioma, H3 K27M-mutant , Voprosy onkologii: Vol. 69 No. 3 (2023)
Mariia Urezkova , Tatyana Semiglazova , Anna Artemyeva , Asel Kudaybergenova , Vladislav Semiglazov , Petr Krivorotko, Vladimir Semiglazov , Results of FISH study of HER2 in triple-positive breast cancer , Voprosy onkologii: Vol. 69 No. 2 (2023)
Marina Popova, Andrey Chekalov, Ivan Tsygankov, Yuliya Rogacheva, Marina Demchenkova, Maria Grigoreva, Olga Uspenskaya, Olga Ruzhinskaya, Vsevolod Potapenko, Nadezhda Medvedeva, Ilya Zyuzgin, Kamil Kaplanov, Tatiana Ksenzova, Alexander Levanov, Olga Samoylova, Nikita Volkov, Anastasya Beynarovich, Artem Gusak, Kirill Lepik, Nataliya Mikhailova, Vadim Baykov, Alexander Kulagin, Burkitt lymphoma in patients with HIV infection: results of a Russian multicenter study , Voprosy onkologii: Vol. 68 No. 6 (2022)
Yevgeniya Kharchenko, Tatyana Semiglazova, Anna Artemeva, Galina Kireeva, I. Polyatskin, Ilya Zyuzgin, Larisa Filatova, Yuliya Chudinovskikh, Margarita Motalkina, Yuliya Oleynik, PROGNOSTIC IMPACT OF IMMUNOHISTOCHEMICAL AND MOLECULAR GENETIC MARKERS IN DIFFUSE LARGE B-CELL LYMPHOMA , Voprosy onkologii: Vol. 66 No. 1 (2020)
Aleksei Koviazin, Larisa Filatova, Ilia Zyuzgin, Anna Artemyeva, Ilia Poliatskin, Leonid Kramynin, Tatiana Semiglazova, The Effect of high-dose chemotherapy with upfront autologous hematopoietic stem cell transplantation on the prognosis of patients with stage IV diffuse large B-cell lymphoma. , Voprosy onkologii: Vol. 69 No. 3 (2023)
Mariya Berkut, Evgeny Naumovich Imyanitov, Vladislav Tiurin, Natalia Mitiushkina , Anna Artemyeva, Alexander Nosov, Clinical Evaluation of the Significance of FGFR2/3 Genomic Alterations in Urothelial Cancer: A Retrospective Analysis , Voprosy onkologii: Vol. 70 No. 4 (2024)
Tatyana Semiglazova, Natalya Buevich, Yekaterina Anokhina, Yevgeniya Kharchenko, Mikhail Osipov, Veronika Klimenko, Margarita Motalkina, Yuriy Komarov, Gulfiya Teletaeva, Dilorom Latipova, Sergey Alekseev, Larisa Filatova, Aleksey Novik, Anna Semenova, Irina Baldueva, Aleksandr Stukov, Svetlana Protsenko, Z. Kotova, HOW APPROACHES TO DRUG THERAPY FOR MALIGNANT TUMORS HAVE CHANGED (TO THE FIRST DOMESTIC ANTITUMOR DRUG IS DEDICATED) , Voprosy onkologii: Vol. 63 No. 2 (2017)
Nadezhda Popova , Sergey Novikov, Pavel Krzhivitsky, Ludmila Zhukova, Petr Krivorotko, Anna Artemyeva, Alina Valitova, Alina Khoroshavina , Antonina Chernaya, Zhanna Bryantseva, Irina Akulova, Aleksandr Mikhnin, Tatyana Yaganova, Sergey V. Kanaev, Diagnostic Capabilities of Scintimammography in Detecting Multicentric and Minimal Breast Cancer of Various Molecular Subtypes , Voprosy onkologii: Vol. 69 No. 4 (2023)
Larisa Filatova, Yevgeniya Kharchenko, Sergey Alekseev, Ilya Zyuzgin, Anna Artemeva, Margarita Motalkina, Tatyana Semiglazova, I. Ishmatova, P. Shilo, PROSPECTS FOR HIGH-DOSE CHEMOTHERAPY WITH AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN THE FIRST LINE OF THERAPY FOR AGGRESSIVE NON-HODGKIN’S LYMPHOMAS , Voprosy onkologii: Vol. 63 No. 2 (2017)
Sergey Alekseev, A. Subora, P. Shilo, I. Ishmatova, Tatyana Semiglazova, Larisa Filatova, Svetlana Kuleva, Yuliya Oleynik, Yuliya Chudinovskikh, Yevgeniya Kharchenko, Margarita Motalkina, Ilya Zyuzgin, S. Shalaev, ANALYSIS OF UNFAVORABLE PROGNOSTIC FACTORS IN PATIENTS WHO RECEIVED HIGH-DOSE CHEMOTHERAPY WITH AUTOLOGOUS STEM-CELL HEMOPOIETIC STEM CELLS TRANSPLANTATION FOR RELAPSES AND RESISTANT FORMS OF HODGKIN''S LYMPHOMA , Voprosy onkologii: Vol. 64 No. 3 (2018)